What to Expect From Corbus Pharmaceuticals in 2018
For a brief few weeks in 2017, it looked like Corbus Pharmaceuticals (NASDAQ: CRBP) could be making another big play after a terrific performance in the previous year. The stock gained more than 20% year to date by late March.
And then it all fell apart. Corbus announced results from a phase 2 study of anabasum in treating cystic fibrosis. Although the company viewed the results as positive, most outside observers didn't. Corbus stock is now down nearly 20% in 2017 despite its promising start.
Will the new year bring a return to glory for the biotech or a continuation of 2017? Here's what to expect from Corbus Pharmaceuticals in 2018.
Source: Fool.com
Corbus Pharmaceuticals Holding Inc. Aktie
52,50 €
7,00 %
Keine klare Meinung bei der Corbus Pharmaceuticals Holding Inc. Aktie: 2 Buy-Einschätzungen stehen 1 Sell-Einschätzungen gegenüber.
Ein unerwartetes Potenzial von -4.76% für Corbus Pharmaceuticals Holding Inc., gegeben ein Kursziel von 50 €, das unter dem aktuellen Kurs von 52.5 € liegt.
